Annual report

Covanta Holding Corporation Announces Successful Receipt of Requisite Consents Related to Consent Solicitations for Certain Outstanding Tax-Exempt Bonds of Niagara Area Development Corporation, National Finance Authority, Pennsylvania Economic Development

Friday, October 15, 2021 - 11:02pm

653542 AD2) (collectively, the "NY Bonds"), (ii) National Finance Authority's Series 2020A Bonds (CUSIP No.

Key Points: 
  • 653542 AD2) (collectively, the "NY Bonds"), (ii) National Finance Authority's Series 2020A Bonds (CUSIP No.
  • 63607Y AJ9) (collectively, the "NH 2020 Bonds"), (iii) National Finance Authority's Series 2018A Bonds (CUSIP No.
  • 63607Y AC4) (collectively, the "NH 2018 Bonds"), (iv) Pennsylvania Economic Development Financing Authority's Series 2019A Bonds (CUSIP No.
  • 708692 BQ0) (the "PA Bonds") and (v) Virginia Small Business Financing Authority's Series 2018A-1 Bonds (CUSIP No.

Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity

Friday, October 15, 2021 - 11:00pm

I remain very impressed by, and enthusiastic about, the innovative science and potential of Enochian BioSciences entire pipeline, said Dr. Piot.

Key Points: 
  • I remain very impressed by, and enthusiastic about, the innovative science and potential of Enochian BioSciences entire pipeline, said Dr. Piot.
  • However, my responsibilities advising a governmental organization do not allow me to continue as a scientific advisor.
  • For more information, please visit Enochianbio.com
    Statements in this press release that are not strictly historical in nature are forward-looking statements.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer

Friday, October 15, 2021 - 10:33pm

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, today announced the appointment of Mark Glickman as the Companys Chief Business Officer.

Key Points: 
  • TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, today announced the appointment of Mark Glickman as the Companys Chief Business Officer.
  • Mr. Glickman previously served as Chief Commercial Officer of Esperion and Aralez Pharmaceuticals, and Executive Vice President, Sales and Marketing, of Auxilium Pharmaceuticals, among other global pharmaceutical roles.
  • Mr. Glickman received his MBA in Finance and International Management from New York University and his BA from State University of New York College at Oswego.
  • To learn more about TherapeuticsMD, please visit therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2021 Financial Results

Friday, October 15, 2021 - 9:36pm

OLDSMAR, Fla., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2021.

Key Points: 
  • OLDSMAR, Fla., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2021.
  • Consolidated revenues for the third quarter of fiscal 2021 were $7.5 million compared to $8.1 million for the third quarter of fiscal 2020.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.
  • Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization.

Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021

Friday, October 15, 2021 - 9:30pm

PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that data from in vitro studies supporting the early preclinical validation of PLA2R-Chimeric AutoAntibody Receptor T (CAART) cell candidates will be presented at ASN Kidney Week 2021. The data will be presented as an oral abstract by Aimee Payne, M.D., Ph.D., Professor of Dermatology at the University of Pennsylvania’s Perelman School of Medicine and co-chair of the Scientific Advisory Board and co-founder at Cabaletta Bio at the American Society of Nephrology (ASN) Kidney Week 2021 being held virtually from November 4-7, 2021.

Key Points: 
  • PLA2R-CAART is one of seven CAAR T programs that have emerged from the Cabaletta Approach to selective B cell Ablation (CABA) platform.
  • The lead preclinical product candidate, MuSK-CAART, is designed as a potential treatment for patients with MuSK-associated myasthenia gravis, with an IND submission planned by the end of 2021.
  • Primary membranous nephropathy (MN) is a B cell-mediated autoimmune disease that affects the kidneys.
  • Approximately 70-80% of the 15,000 primary MN patients in the U.S. have autoantibodies directed to the phospholipase A2 receptor (PLA2R) on kidney podocytes.

ICE Announces Completion of Merger Between Bakkt and VPC Impact Acquisition Holdings

Friday, October 15, 2021 - 9:15pm

ICE maintains an approximately 68% economic interest and a minority voting interest in the combined company.

Key Points: 
  • ICE maintains an approximately 68% economic interest and a minority voting interest in the combined company.
  • The investment will be reclassified as an equity method investment of ICE and will therefore not be consolidated within ICEs financial statements.
  • Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds and operates digital networks to connect people to opportunity.
  • Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange.

Gulf Coast Ultra Deep Royalty Trust Announces Quarterly Cash Distribution

Friday, October 15, 2021 - 9:15pm

About Gulf Coast Ultra Deep Royalty Trust.

Key Points: 
  • About Gulf Coast Ultra Deep Royalty Trust.
  • The subject interests and the Trusts overriding royalty interests are described in the Trusts filings with the Securities and Exchange Commission (SEC).
  • Any differences in actual cash receipts by the Trust could affect the amount of quarterly cash distributions.
  • If you have any questions related to the Trust, please see below for contact information:
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211015005073/en/

Hertz Files Registration Statement for Public Offering of Common Stock by Selling Stockholders

Friday, October 15, 2021 - 9:57pm

ESTERO, Fla., Oct. 15, 2021 /PRNewswire/ -- Hertz Global Holdings, Inc. (OTCPK:HTZZ) ("Hertz" or the "Company") announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed public offering of its common stock.

Key Points: 
  • ESTERO, Fla., Oct. 15, 2021 /PRNewswire/ -- Hertz Global Holdings, Inc. (OTCPK:HTZZ) ("Hertz" or the "Company") announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed public offering of its common stock.
  • The shares of common stock to be sold in the offering are anticipated to be offered by certain of the Company's stockholders.
  • Hertz's common stock currently trades on the over-the-counter market under the symbol "HTZZ".
  • Hertz intends to apply to list its common stock on the Nasdaq Global Select Market under the symbol "HTZ" in connection with the offering.

Helbiz Announces Google Workspace Integration to Enhance Data Security

Friday, October 15, 2021 - 7:14pm

Helbiz Inc. (Nasdaq: HLBZ), a global leader in micro-mobility and the first in its industry to be publicly listed on the Nasdaq Stock Market, today announced the integration of Google Workspace to further enhance the security of its users' data and improve business efficiency.

Key Points: 
  • Helbiz Inc. (Nasdaq: HLBZ), a global leader in micro-mobility and the first in its industry to be publicly listed on the Nasdaq Stock Market, today announced the integration of Google Workspace to further enhance the security of its users' data and improve business efficiency.
  • Beginning today, Helbiz will benefit from the main security features of Google Workspace Enterprise Plus to protect company and user data with multi-layered security options such as comprehensive security and compliance tools, data loss prevention, advance anti-phishing and malware, two-step verification, while enterprise endpoint management will protect data in the event of device loss or staff turnover.
  • "Data security is one of the most important issues at Helbiz for both our company and our users worldwide," said Ruggero Cipriani Foresio, Chief Marketing Officer of Helbiz.
  • "Thanks to Google Workspace, we can guarantee efficiency and advanced data protection as we create an increasingly transparent working environment and relationship with our customers.

Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market

Friday, October 15, 2021 - 6:40pm

The BiCNU brand and generic market had U.S. sales of approximately $19.4 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health*.

Key Points: 
  • The BiCNU brand and generic market had U.S. sales of approximately $19.4 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health*.
  • Dr. Reddys Carmustine for Injection, USP is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg Carmustine USP and a vial containing 3 mL sterile diluent.
  • Please click here for full prescribing information including boxed warning: https://www.drreddys.com/media/1019198/carmustine-for-inj-leaflet.pdf
    Carmustine causes suppression of marrow function (including thrombocytopenia and leukopenia), which may contribute to bleeding and overwhelming infections.
  • Adjust dosage based on nadir blood counts from the prior dose [see Dosage and Administration (2.1)].